+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial



Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial



Plos Neglected Tropical Diseases 4(12): E912



Cutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with decreasing rate cures. Miltefosine is an oral medication with anti-leishmania activity and may increase the cure rates and improve compliance. This study is a randomized, open-label, controlled clinical trial aimed to evaluate the efficacy and safety of miltefosine versus pentavalent antimony (Sb(v)) in the treatment of patients with CL caused by Leishmania braziliensis in Bahia, Brazil. A total of 90 patients were enrolled in the trial; 60 were assigned to receive miltefosine and 30 to receive Sb(v). Six months after treatment, in the intention-to-treat analyses, the definitive cure rate was 53.3% in the Sb(v) group and 75% in the miltefosine group (difference of 21.7%, 95% CI 0.08% to 42.7%, p = 0.04). Miltefosine was more effective than Sb(v) in the age group of 13-65 years-old compared to 2-12 years-old group (78.9% versus 45% p = 0.02; 68.2% versus 70% p = 1.0, respectively). The incidence of adverse events was similar in the Sb(v) and miltefosine groups (76.7% vs. 78.3%). Vomiting (41.7%), nausea (40%), and abdominal pain (23.3%) were significantly more frequent in the miltefosine group while arthralgias (20.7%), mialgias (20.7%) and fever (23.3%) were significantly more frequent in the Sb(v) group. This study demonstrates that miltefosine therapy is more effective than standard Sb(v) and safe for the treatment of CL caused by Leishmania braziliensis in Bahia, Brazil. Clinicaltrials.gov Identifier NCT00600548.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054389560

Download citation: RISBibTeXText

PMID: 21200420

DOI: 10.1371/journal.pntd.0000912


Related references

Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. American Journal of Tropical Medicine and Hygiene 84(2): 255-260, 2011

Fluconazole in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis: A Randomized Controlled Trial. Clinical Infectious Diseases 64(1): 67-71, 2017

A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. American Journal of Tropical Medicine and Hygiene 77(4): 640-646, 2007

Leishmaniasis in Brazil 15 Biochemical distinction of Leishmania mexicana amazonensis, L braziliensis braziliensis and L braziliensis guyanensis - aetiological agents of cutaneous leishmaniasis; in the Amazon Basin of Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene 75.4: 524-529, 1981

Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial. Clinical Infectious Diseases 68(5): 844-849, 2019

Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with helminths and Leishmania braziliensis. American Journal of Tropical Medicine and Hygiene 84(4): 551-555, 2011

Disseminated cutaneous leishmaniasis caused by Leishmania braziliensis in Southern Brazil. Revista do Instituto de Medicina Tropical de Sao Paulo 59: E37, 2017

Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. American Journal of Tropical Medicine and Hygiene 75(6): 1074-1077, 2006

Miltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia. American Journal of Tropical Medicine and Hygiene 99(5): 1153-1155, 2018

Human american cutaneous leishmaniasis leishmania braziliensis braziliensis in brazil lymphoproliferative responses and influence of therapy. Clinical & Experimental Immunology 64(2): 269-276, 1986

Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clinical Infectious Diseases 40(8): 1148-1155, 2005

Reservoir hosts of leishmania braziliensis braziliensis in a peculiar and coastal sited focus of cutaneous leishmaniasis in ceara state brazil. Memorias do Instituto Oswaldo Cruz 82(Suppl. 1): 200, 1987

Cases of american cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis in the towns of Cosmópolis and Indaiatuba-region of Campinas, in São Paulo, Brazil. Revista Da Sociedade Brasileira de Medicina Tropical 29(5): 419-424, 1996

Disseminated American muco-cutaneous leishmaniasis caused by Leishmania braziliensis braziliensis in a patient with AIDS: a case report. Memorias do Instituto Oswaldo Cruz 87(4): 487-492, 1992

An outbreak of American cutaneous leishmaniasis (Leishmania braziliensis braziliensis) in a periurban area of Rio de Janeiro city, Brazil: clinical and epidemiological studies. Memorias do Instituto Oswaldo Cruz 83(4): 427-435, 1988